Clinuvel Pharmaceuticals Ltd

CUV

Company Profile

  • Business description

    Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

  • Contact

    535 Bourke Street
    Level 22
    MelbourneVIC3000
    AUS

    T: +61 396604900

    https://www.clinuvel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    19

Stocks News & Analysis

stocks

Undervalued ASX listed biotech refocuses

Fair value uneffected by suspended early-stage clinical trials.
funds

10 reasons many fund managers are now blank spaces

It looks easy from the outside, but asset management is a tough game. Winners can win big, but there are far more strugglers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,038.1095.00-1.17%
CAC 407,858.8317.53-0.22%
DAX 4022,390.84149.14-0.66%
Dow JONES (US)42,225.32235.360.56%
FTSE 1008,608.4826.32-0.30%
HKSE22,823.45379.08-1.63%
NASDAQ17,601.05151.160.87%
Nikkei 22534,673.691,052.18-2.95%
NZX 50 Index12,284.7635.43-0.29%
S&P 5005,670.9737.900.67%
S&P/ASX 2007,843.8090.70-1.14%
SSE Composite Index3,337.3012.83-0.38%

Market Movers